Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ORACLE: A Long-term Follow-up Study to Evaluate the Safety and Durability of GT005 in Participants With Geographic Atrophy, Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Trial Profile

ORACLE: A Long-term Follow-up Study to Evaluate the Safety and Durability of GT005 in Participants With Geographic Atrophy, Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GT 005 (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms ORACLE
  • Sponsors Gyroscope Therapeutics

Most Recent Events

  • 02 Nov 2023 Planned number of patients changed from 300 to 225.
  • 02 Nov 2023 Planned End Date changed from 16 Sep 2028 to 2 Jun 2028.
  • 02 Nov 2023 Planned primary completion date changed from 16 Mar 2028 to 2 Jun 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top